Skip to main content
Equibles

AARTIPHARM · Aarti Pharmalabs Limited · Documents

Use AARTIPHARM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AARTIPHARM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
999.35 INR -9.65 (-0.96%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 35.75K Avg daily vol (3M) 41.47K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Oct 29, 2026
2026
Oct 29
Earnings call
Q2 revenue rises 47%, CDMO growth guidance maintained

Aarti Pharmalabs reported Q2 FY27 revenue of INR613 crores, up 47% Y-o-Y, with EBITDA of INR136 crores and PAT of INR66 crores. It maintained 40% to 50% CDMO revenue growth guidance and targets full Xanthine capacity by end of FY27.

5 source passages
Moving on to our standalone financial for Q2 FY27, Aarti Pharmalabs maintained strong momentum delivering its highest ever quarterly revenue of INR613 crores as compared to INR417 crores, which is 47% increase Y-o-Y basis. The EBITDA was INR136 crores as compared to INR74 crores in the corresponding previous period of the previous year and that is an increase of 84% Y-o-Y. The profit after tax for the Q2 financial year 27 was INR66 crores as compared to INR24 crores a year back, which is which was 2.75x the increase on last year's low base. We remain on track to achieve our target of 40% to 50% revenue growth over last year on this business segment. The ramp-up of xanthine expanded capacity is progressing and we plan to achieve the full capacity by the end of FY27 and we will achieve the utilization sequentially in the next year. Open the document at this passage
Showing 1–3 of 3 documents